CD8A and cancer: Gemcitabine may diminish the number of circulating immunosuppressive cells (i.e., MDSCs) and induce the expression of MHC-I (major histocompatibility complex) in cancer cells (increasing antigenicity) [27], which supports the function of CD8+ cells.